HNMI Q4 Operating Profit Up 12% to HKD 1.2B

HanmiPharm (HNMI) reported Q4 operating profit of HKD 1.2 billion, up 12% from HKD 1.07 billion in the same period of 2025, according to the company's earnings release dated February 5, 2026. The increase followed strong sales growth in its generics and branded pharmaceuticals segments, with revenue rising 8% year-over-year to HKD 4.1 billion. Management attributed the improvement to higher volumes and pricing in key markets, as well as cost optimization initiatives. The stock closed at HKD 48.20 on February 4, 2026, up 2.1% for the session.